Key facts
- Particella’s last known valuation is $21.1M (Apr 2022).
- It has raised $13.0M; the latest was Later Stage VC in Jan 2025.
- Notable investors include SOSV, IndieBio, University of California, SeedFolio, Baldota (Electrical Equipment) — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Particella
- ·The full record, as it builds
Funding rounds
No funding rounds for Particella are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Particella
Developer of an oral lipid nanoparticle technology designed to deliver nucleic acids to the intestinal epithelium. The company focuses on oral mRNA medicines with repeatable dosing and non-immunogenic properties, enabling healthcare providers to administer nucleic acid therapeutics through oral delivery.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2016
- Employees
- 7
- Website
- particella.bio/
- Ownership
- Privately Held (backing)
Particella doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Particella shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Particella in its N-PORT filings yet. We sweep new filings monthly.